NASDAQ:BWV Onconetix (BWV) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free BWV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.18▼$0.2050-Day Range$0.18▼$0.1852-Week Range$0.18▼$1.95Volume534,200 shsAverage Volume795,235 shsMarket Capitalization$3.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsEarningsOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsOwnershipShort InterestSocial Media Get Onconetix alerts: Email Address Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About Onconetix Stock (NASDAQ:BWV)Blue Water Biotech, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Vaccines, Inc. and changed its name to Blue Water Biotech, Inc. in April 2023. Blue Water Biotech, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Read More Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. BWV Stock News HeadlinesDecember 22, 2023 | seekingalpha.comBWV Blue Water Biotech, Inc.December 19, 2023 | finanznachrichten.deBlue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to OnconetixMay 9, 2024 | Weiss Ratings (Ad)The ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …December 18, 2023 | markets.businessinsider.comBlue Water Biotech Acquires Proteomedix AGDecember 18, 2023 | finance.yahoo.comBlue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™December 15, 2023 | wsj.comBlue Water Biotech Inc.See More Headlines Receive BWV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconetix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:BWV CUSIPN/A CIK1782107 Webwww.bwbioinc.com Phone513-620-4101FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-108.19% Return on Assets-66.47% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.63 per share Price / Book0.11Miscellaneous Outstanding Shares18,660,000Free Float15,017,000Market Cap$3.36 million OptionableNot Optionable Beta3.58 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. James R. Sapirstein M.B.A. (Age 62)R.Ph., Interim Executive Chairman Comp: $65.62kMs. Erin Henderson (Age 48)Chief Business Officer & Corporate Secretary Comp: $526.9kDr. Neil J. Campbell MA (Age 63)MBA, President, CEO & Director Mr. Bruce Harmon (Age 65)Chief Financial Officer Dr. Brian Price Ph.D.Head of Technology StrategyMr. Frank A. Jaeger M.A. (Age 52)M.B.A., Senior VP of Marketing & Business Development Mr. Andrew D. Skibo Ph.D.Global Head of Biologics OperationsMr. Theodore Scott YohoHead of Business DevelopmentDr. Ali I. Fattom Ph.D.Head of Science & DiscoveryDr. Jay Newmark M.B.A.M.D., Chief Medical OfficerMore ExecutivesKey CompetitorsEiger BioPharmaceuticalsNASDAQ:EIGR9 Meters BiopharmaNASDAQ:NMTRPHAXIAM TherapeuticsNASDAQ:PHXMG Medical InnovationsNASDAQ:GMVDFFinch Therapeutics GroupNASDAQ:FNCHView All Competitors BWV Stock Analysis - Frequently Asked Questions Should I buy or sell Onconetix stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconetix in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BWV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BWV, but not buy additional shares or sell existing shares. View BWV analyst ratings or view top-rated stocks. When did Onconetix IPO? Onconetix (BWV) raised $20 million in an IPO on Friday, February 18th 2022. The company issued 2,222,222 shares at $9.00 per share. This page (NASDAQ:BWV) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetryThe Crypto 9-5 Escape PlanCrypto 101 Media348 million Americans lives to END as we know it?The Oxford ClubThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
